Artificially or naturally expressed Notch ^MUT restored sensitivity to anti–PD-L1. (A) Tumor volume in LLC-bearing mice following anti–PD-L1 mAb, Bpmel-Notch2^MUT cell adjuvant (Bpmel-Notch2^MUT), or combination therapy (Bpmel-Notch2^MUT + PD-L1 mAb) (n = 5 per group). (B) The percentage of central memory (CD44⁺Ly6C⁺) and CX3CR1⁺ population in CD8⁺ T cell in DLN. (C) The percentage of effector memory (CD62L⁻CD44⁺) among Foxp3⁻ CD4⁺ T cells, Ki67⁺ Foxp3⁻ cells in CD4⁺ T cells, and Ki67⁺ Foxp3⁺ cells in CD4⁺ T cells in DLN. (D) The percentage of CD8⁺ or CD4⁺ T cells among the CD45⁺ population in LLC tumors (n = 4 per group on day 12). (E and F) FCM analysis of CD39, PD1, TIM3, SLAMF6, and CD127 expression in tumor-infiltrating CD8⁺ T cells on day 12 (n = 4 per group). (G) The experimental procedure of anti–PD-L1 and cell adjuvant combination therapy (upper panel). LLC tumor volume in mice treated with MC38 as a cell adjuvant or Bpmel-OVAI as a negative control combined with anti–PD-L1 antibody is shown (n = 5 per group). P value was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. All data are representative of three similar experiments.